[{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1\/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Acuitas","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Hatteras Investment Partners","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Myeloid Therapeutics
The Proceeds will support the clinical development of MT-101, Myeloid’s lead cell therapy program in Phase 1/2 for T cell lymphoma, and will accelerate the development of MT-302, a first-in-class TROP2-FcA mRNA-LNP product, into a Phase 1/2 for TROP2-expressing tumors.
Through this agreement, Myeloid de-risks the development of its candidates by leveraging Acuitas’ science and proven regulatory, to rapidly translate Myeloid’s innovation to patients. The MT-301 and MT-302 programs will utilize Acuitas’ LNP deliver technology.
Myeloid dosed MT-101 in a patient with refractory PTCL within 18 months, illustrating the potential of mRNA therapies to help patients sooner and to accelerate Myeloid's portfolio.
Myeloid has advanced its lead development candidates including MT-101 through preclinical studies, implemented its manufacturing platform and plans to dose patients in the first half of this year.